Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06967610 · ClinicalTrials.gov registry record · Phase 2

Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).

A Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (SLL), sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
1
Study location

NCT06967610: Recruiting Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (SLL), sponsored by M.D. Anderson Cancer Center.

NCT06967610 is a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (SLL) that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 40 participants, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (78% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT06967610, a Phase 2 study of Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (SLL), is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
1
Study location

Study Summary

To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.

Primary Outcome

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5

Conditions Studied

Chronic Lymphocytic Leukemia Small Lymphocytic Leukemia (SLL)

Interventions

  • DRUG Obinutuzumab
  • DRUG Venetoclax
  • DRUG Pirtobrutinib

Study Locations (1)

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-07-15
Est. Completion 2033-06-01
Phase Phase 2
M.D. Anderson Cancer Center

2,692 total trials

What NCT06967610 shows while recruiting

NCT06967610 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 182-participant average among 187 other Chronic Lymphocytic Leukemia trials with a reported enrollment target (78% lower).

The record links to 2 conditions, with Chronic Lymphocytic Leukemia appearing as the primary indexed condition, and to 3 interventions - of which Obinutuzumab is the first listed.

NCT06967610 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT06967610 about?

NCT06967610 is a clinical study titled "Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).". To learn if the drug combination pirtobrutinib, venetoclax, and obinutuzumab can help to control relapsed CLL/SLL.

What is the current status of trial NCT06967610?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-07-15. Estimated completion is 2033-06-01.

What conditions does trial NCT06967610 study?

This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia (SLL).

What interventions are being tested in trial NCT06967610?

The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Pirtobrutinib (DRUG).

Who is sponsoring clinical trial NCT06967610?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06967610 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Lymphocytic Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06967610's enrollment target sits among peer trials

40 115th of 187 higher than 67 of 187 other Chronic Lymphocytic Leukemia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06967610

Source: ClinicalTrials.gov NCT06967610, the US trial registry maintained by the National Library of Medicine. NCT06967610 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.